-
131I治疗作为DTC术后重要的靶向治疗手段,可清除残存甲状腺组织中的微小癌灶,降低复发率、减少远处转移,有效改善患者预后[1-2]。131I释放的γ射线会对周围环境造成放射性污染,对医护及陪护人员也会造成辐射损伤,因此131I治疗后必须对患者进行放射性隔离防护[3]。辐射防护是放射性核素治疗中不可或缺的一部分,国内多数医院规定了固定统一的辐射隔离时间,导致部分患者隔离时间长,造成医疗资源的浪费。鉴于此,本研究采用放射性核素治疗监护机器人(又称为智能陪护机器人)测量辐射隔离患者的辐射剂量,探究131I治疗DTC术后患者全身辐射剂量代谢的影响因素,为其辐射防护提供指导。
-
由图1可见,131I治疗DTC术后患者全身辐射剂量在服药后24 h时达到最高,之后逐渐下降,在48 h时接近安全值(23.30 μSv/h)。
-
由表1可知,安全组患者32例、危险组患者40例;危险组2 h摄碘率、24 h摄碘率、FT3和FT4水平均高于安全组,且差异均有统计学意义(均P<0.05);危险组Tg水平各量级分布与安全组的差异有统计学意义(P=0.01);危险组存在超声残甲的患者多于安全组,且差异有统计学意义(P=0.03);2组患者的性别、年龄、TgAb水平的差异均无统计学意义(均P>0.05)。
指标 安全组(n=32) 危险组(n=40) 检验值 P值 甲状腺2 h摄碘率( ,%)$ \bar{x}\pm s $ 5.40±0.96 6.05±1.16 t=−2.56 0.01 甲状腺24 h摄碘率[ M(IQR),%] 3.05(1.70) 4.20(5.50) Z=−2.07 0.04 FT3[ M(IQR),pmol/L] 1.19(0.52) 1.63(1.02) Z=−2.83 0.01 FT4[ M(IQR),pmol/L] 3.02(1.01) 4.16(2.19) Z=−2.70 0.01 TSH[ M(IQR),mIU/L] 137.39(28.65) 123.45(75.31) Z=−1.65 0.10 性别 [例(%)] 男 10(31.25) 17(42.50) χ2=0.96 0.33 女 22(68.75) 23(57.50) 年龄 [例(%)] ≤40岁 18(56.25) 19(47.50) χ2=0.55 0.46 >40岁 14(43.75) 21(52.50) Tg水平 [例(%)] <3.50 ng/ml 17(53.13) 10(25.00) χ2=6.80 0.01 3.50~77.00 ng/ml 13(40.63) 23(57.50) 78.00~500.00 ng/ml 2(6.25) 3(7.50) >500.00 ng/ml 0(0) 4(10.00) TgAb水平[例(%)] ≤110 IU/ml 25(78.13) 38(95.00) − 0.07 >110 IU/ml 7(21.88) 2(5.00) 甲状腺超声提示是否存在
甲状腺残留组织[例(%)]否 28(87.50) 25(62.50) − 0.03 是 4(12.50) 15(37.50) 注: FT3为游离三碘甲腺原氨酸;IQR为四分位间距;FT4为游离甲状腺素;TSH为促甲状腺激素;Tg为甲状腺球蛋白;TgAb为甲状腺球蛋白抗体。−表示采用Fisher确切概率法,无检验值 表 1 2组131I治疗分化型甲状腺癌术后患者全身辐射剂量代谢影响因素的单因素分析结果
Table 1. Univariate analysis results of influencing factors of whole body radiation dose metabolism in 2 groups of postoperative patients with differentiated thyroid cancer after iodine-131 treatment
-
多因素Logistics回归分析结果显示,24 h摄碘率[OR=1.27(95%CI:1.03~1.57)]和Tg水平[OR=2.51(95%CI:1.21~5.20)]对全身辐射剂量代谢有影响(P=0.03、0.01),24 h摄碘率和Tg水平越高的患者其48 h全身辐射剂量达到安全水平的可能性越低。
-
根据多因素Logistic回归分析结果建立24 h摄碘率+Tg水平(联合指标)诊断的预测公式:y=−2.49+0.24×24 h摄碘率+0.92×Tg水平。ROC曲线分析结果显示,联合指标的诊断效能明显优于其他单一指标(图2)。由表2可知,联合指标的AUC为0.76(95%CI:0.65~0.87)、灵敏度为94.87%、特异度为46.88%、最佳临界值为−0.71,当患者的联合指标>−0.71时,则认为该患者处于危险期还需要继续留院观察;反之,则认为患者处于安全期可解除隔离。
图 2 不同指标对分化型甲状腺癌术后患者131I治疗后48 h全身辐射剂量预测的受试者工作特征曲线
Figure 2. Receiver operating characteristic curve of various indicators for the prediction of total body radiation dose 48 h after iodine-131 treatment in postoperative patients with differentiated thyroid cancer
指标 曲线下面积 (95%CI) 最佳临界值 灵敏度(%) 特异度(%) P值 24 h摄碘率+Tg水平 0.76(0.65~0.87) −0.71 94.87 46.88 <0.01 甲状腺2 h摄碘率 0.65(0.53~0.78) 6.40(%) 38.46 90.62 0.03 甲状腺24 h摄碘率 0.64(0.52~0.77) 3.80(%) 51.28 81.25 0.04 游离三碘甲腺原氨酸(FT3) 0.69(0.56~0.81) 1.62(pmol/L) 50.00 90.62 0.01 游离甲状腺素(FT4) 0.68(0.55~0.81) 3.84(pmol/L) 55.00 81.25 0.01 甲状腺球蛋白(Tg) 0.66(0.53~0.79) 3.5(ng/ml) 75.00 53.13 0.02 甲状腺超声提示是否存在甲状腺残留组织 0.62(0.49~0.75) 是 35.90 87.50 0.10 表 2 不同指标对分化型甲状腺癌术后患者131I治疗后48 h全身辐射剂量诊断的最佳临界值及效能
Table 2. The optimal critical value of various indicators for the diagnosis of whole body radiation dose 48 h after iodine-131 treatment in postoperative patients with differentiated thyroid cancer
131I治疗分化型甲状腺癌术后患者辐射剂量预测模型的研究
Prediction model of radiation dose in patients with differentiated thyroid cancer after 131I treatment
-
摘要:
目的 探讨131I治疗分化型甲状腺癌(DTC)术后患者全身辐射剂量代谢的影响因素,为辐射防护提供指导。 方法 回顾性分析2018年4至9月于3家三甲医院住院的72例DTC术后患者[男性27例、女性45例,年龄15~75(42.79±14.23)岁]的临床资料,其中同济大学附属第十人民医院23例、上海交通大学医学院附属仁济医院24例、华中科技大学同济医学院附属协和医院25例。根据服用131I后48 h全身辐射剂量是否达到安全标准将患者分为安全组(48 h全身辐射剂量≤23.30 μSv/h)和危险组(48 h全身辐射剂量>23.30 μSv/h),比较各因素对全身辐射剂量代谢的影响。计量资料的组间比较采用成组t检验或Wilcoxon秩和检验;计数资料的组间比较采用卡方检验或Fisher确切概率法。对各变量进行单因素分析,对单因素分析中差异有统计学意义的变量采用多因素Logistic回归分析。以各单因素及多因素联合指标绘制受试者工作特征(ROC)曲线,评估其最佳临界值及诊断效能。 结果 危险组和安全组比较的单因素分析结果显示,甲状腺2 h摄碘率(t=−2.56,P=0.01)、24 h摄碘率(Z=−2.07,P=0.04)、游离三碘甲腺原氨酸(Z=−2.83,P=0.01)、游离甲状腺素(Z=−2.70,P=0.01)、甲状腺球蛋白(Tg)水平(χ2=6.80,P=0.01)、甲状腺超声提示是否存在甲状腺残留组织(Fisher确切概率法,P=0.03)等6个指标显著影响了131I治疗DTC术后患者的全身辐射剂量代谢。多因素Logistic回归分析结果显示,24 h摄碘率[OR=1.27(95%CI:1.03~1.57)]和Tg水平[OR=2.51(95%CI:1.21~5.20)]对全身辐射剂量代谢有影响(P=0.03、0.01),24 h摄碘率和Tg水平越高的患者其48 h全身辐射剂量达到安全水平的可能性越低。24 h摄碘率+Tg水平(联合指标)诊断的ROC曲线下面积为0.76(95%CI:0.65~0.87)、灵敏度为94.87%、特异度为46.88%、最佳临界值为−0.71。 结论 24 h摄碘率和Tg水平是131I治疗DTC术后患者全身辐射剂量代谢的影响因素,利用这两个因素建立联合指标进行辐射剂量评估可为调整患者住院时长提供参考。 Abstract:Objective To explore the factors affecting the metabolic rate of 131I radiation dose in vivo in patients with differentiated thyroid cancer (DTC) after surgery and 131I treatment to provide guidance for radiation protection. Methods A retrospective analysis was conducted on 72 postoperative patients with DTC (27 males and 45 females, aged 15–75 (42.79±14.23) years old) who were hospitalized in the department of nuclear medicine of three grade 3A hospitals from April to September in 2018. Among the above mentioned patients, 23 were from the Tenth People's Hospital Affiliated to Tongji University, 24 were from Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, and 25 were from Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology. The patients were divided into safety groups (48 h whole body radiation dose≤23.30 μSv/h) and risk groups (48 h whole body radiation dose>23.30 μSv/h) depending on whether the whole body radiation dose reached the safety standard 48 h after taking 131I, and the effects of various factors on the whole body radiation dose metabolism between the two groups were compared. The measurement data were compared by group t test or Wilcoxon rank sum test; the intergroup comparison of enumeration data was examined by chi-square test or Fisher's exact test. Univariate analysis was performed on each variable, and multivariate Logistic regression analysis was conducted for variables that were statistically significant in univariate analysis. The receiver operating characteristic (ROC) curve was drawn using each univariate indicator and combined indicators to determine the best critical value and diagnostic efficacy for predicting the efficacy of 131I. Results The univariate analysis results of the comparison between the risk group and the safety group showed that the levels of thyroid iodine uptake rate at 2 h (t=−2.56, P=0.01), iodine uptake rate at 24 h (Z=−2.07, P=0.04), free triiodothyronine (Z=−2.83, P=0.01), free thyroxine (Z=−2.70, P=0.01), thyroglobulin (Tg) (χ2=6.80, P=0.01), and the presence of residual thyroid tissue in ultrasound examination (Fisher's exact test, P=0.03) significantly affected the metabolism of whole body radiation dose in patients with DTC after 131I treatment. The results of multivariate Logistic regression analysis showed that the 24 h iodine uptake rate (OR=1.27(95%CI: 1.03–1.57)), Tg level (OR=2.51(95%CI: 1.21–5.20)) influenced whole body radiation dose metabolism (P=0.03, 0.01). The higher the 24 h iodine uptake rate and the higher the Tg level, the lower the probability that the 48 h whole body radiation dose reached a safe level. The area under the ROC curve of the combined diagnostic index of 24 h iodine uptake rate and Tg level was 0.76(95%CI: 0.65–0.87). The sensitivity was 94.87%, the specificity was 46.88%, and the best critical value was −0.71. Conclusions The 24 h iodine uptake rate and Tg level were the influencing factors of radiation dose metabolism in patients with DTC after 131I treatment. Therefore, these two factors can be used to establish a combined index to evaluate radiation dose, providing a basis for adjusting the length of hospitalization of patients. -
Key words:
- Thyroid neoplasms /
- Iodine radioisotopes /
- Brachytherapy /
- Radiation dosage /
- Prediction model
-
表 1 2组131I治疗分化型甲状腺癌术后患者全身辐射剂量代谢影响因素的单因素分析结果
Table 1. Univariate analysis results of influencing factors of whole body radiation dose metabolism in 2 groups of postoperative patients with differentiated thyroid cancer after iodine-131 treatment
指标 安全组(n=32) 危险组(n=40) 检验值 P值 甲状腺2 h摄碘率( ,%)$ \bar{x}\pm s $ 5.40±0.96 6.05±1.16 t=−2.56 0.01 甲状腺24 h摄碘率[ M(IQR),%] 3.05(1.70) 4.20(5.50) Z=−2.07 0.04 FT3[ M(IQR),pmol/L] 1.19(0.52) 1.63(1.02) Z=−2.83 0.01 FT4[ M(IQR),pmol/L] 3.02(1.01) 4.16(2.19) Z=−2.70 0.01 TSH[ M(IQR),mIU/L] 137.39(28.65) 123.45(75.31) Z=−1.65 0.10 性别 [例(%)] 男 10(31.25) 17(42.50) χ2=0.96 0.33 女 22(68.75) 23(57.50) 年龄 [例(%)] ≤40岁 18(56.25) 19(47.50) χ2=0.55 0.46 >40岁 14(43.75) 21(52.50) Tg水平 [例(%)] <3.50 ng/ml 17(53.13) 10(25.00) χ2=6.80 0.01 3.50~77.00 ng/ml 13(40.63) 23(57.50) 78.00~500.00 ng/ml 2(6.25) 3(7.50) >500.00 ng/ml 0(0) 4(10.00) TgAb水平[例(%)] ≤110 IU/ml 25(78.13) 38(95.00) − 0.07 >110 IU/ml 7(21.88) 2(5.00) 甲状腺超声提示是否存在
甲状腺残留组织[例(%)]否 28(87.50) 25(62.50) − 0.03 是 4(12.50) 15(37.50) 注: FT3为游离三碘甲腺原氨酸;IQR为四分位间距;FT4为游离甲状腺素;TSH为促甲状腺激素;Tg为甲状腺球蛋白;TgAb为甲状腺球蛋白抗体。−表示采用Fisher确切概率法,无检验值 表 2 不同指标对分化型甲状腺癌术后患者131I治疗后48 h全身辐射剂量诊断的最佳临界值及效能
Table 2. The optimal critical value of various indicators for the diagnosis of whole body radiation dose 48 h after iodine-131 treatment in postoperative patients with differentiated thyroid cancer
指标 曲线下面积 (95%CI) 最佳临界值 灵敏度(%) 特异度(%) P值 24 h摄碘率+Tg水平 0.76(0.65~0.87) −0.71 94.87 46.88 <0.01 甲状腺2 h摄碘率 0.65(0.53~0.78) 6.40(%) 38.46 90.62 0.03 甲状腺24 h摄碘率 0.64(0.52~0.77) 3.80(%) 51.28 81.25 0.04 游离三碘甲腺原氨酸(FT3) 0.69(0.56~0.81) 1.62(pmol/L) 50.00 90.62 0.01 游离甲状腺素(FT4) 0.68(0.55~0.81) 3.84(pmol/L) 55.00 81.25 0.01 甲状腺球蛋白(Tg) 0.66(0.53~0.79) 3.5(ng/ml) 75.00 53.13 0.02 甲状腺超声提示是否存在甲状腺残留组织 0.62(0.49~0.75) 是 35.90 87.50 0.10 -
[1] He Y, Pan MZ, Huang JM, et al. Iodine-131: an effective method for treating lymph node metastases of differentiated thyroid cancer[J]. Med Sci Monit, 2016, 22: 4924−4928. DOI: 10.12659/MSM.899028. [2] Raruenrom Y, Sawangsri K, Somboonporn C, et al. An impact of microscopic positive margin on incomplete response after I-131 treatment in differentiated thyroid cancer[J]. Ann Nucl Med, 2020, 34(7): 453−459. DOI: 10.1007/s12149-020-01467-6. [3] Verburg FA, Hoffmann M, Iakovou I, et al. Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies[J]. Eur J Nucl Med Mol Imaging, 2020, 47(3): 519−522. DOI: 10.1007/s00259-019-04580-5. [4] Markantes GK, Tsochatzis S, Panagopoulos K, et al. A shift to more targeted thyroidectomies increased the detection of thyroid cancer and in particular low-risk papillary tumors in Southwestern Greece the decade 2007 to 2016[J/OL]. Laryngoscope Investig Otolaryngol, 2020, 5(6): 1260−1265[2021-02-03]. https://onlinelibrary.wiley.com/doi/10.1002/lio2.504. DOI: 10.1002/lio2.504. [5] Davies L, Hoang JK. Thyroid cancer in the USA: current trends and outstanding questions[J]. Lancet Diabetes Endocrinol, 2021, 9(1): 11−12. DOI: 10.1016/S2213-8587(20)30372-7. [6] Gui ZQ, Wang ZH, Xiang JZ, et al. Comparison of outcomes following thyroid isthmusectomy, unilateral thyroid lobectomy, and total thyroidectomy in patients with papillary thyroid microcarcinoma of the thyroid isthmus: a retrospective study at a single center[J]. Med Sci Monit, 2020, 26: e927407. DOI: 10.12659/MSM.927407. [7] Altedlawi Albalawi IA 2nd, Altidlawi AI, Mirghani H. Radioactive iodine following total thyroidectomy is comparable to lobectomy in low/intermediate-risk differentiated thyroid carcinoma: a meta-analysis[J/OL]. Cureus, 2020, 12(12): e12332[2021-02-03]. https://www.cureus.com/articles/48479-radioactive-iodine-following-total-thyroidectomy-is-comparable-to-lobectomy-in-lowintermediate-risk-differentiated-thyroid-carcinoma-a-meta-analysis. DOI: 10.7759/cureus.12332. [8] Grani G, Lamartina L, Alfò M, et al. Selective use of radioactive iodine therapy for papillary thyroid cancers with low or lower-intermediate recurrence risk[J]. J Clin Endocrinol Metab, 2021, 106(4): e1717−e1727. DOI: 10.1210/clinem/dgaa973. [9] Dotinga M, Vriens D, van Velden F, et al. Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy[J]. Q J Nucl Med Mol Imaging, 2020, 64(3): 250−264. DOI: 10.23736/S1824-4785.20.03264-1. [10] 武含露, 闫志华, 李祥周, 等. 分化型甲状腺癌患者131I治疗后诊断性全身显像周围剂量当量率动态变化的研究[J]. 国际放射医学核医学杂志, 2020, 44(4): 212−216. DOI: 10.3760/cma.j.cn121381-201907038-00023.
Wu HL, Yan ZH, Li XZ, et al. Study on the dynamic change in ambient dose equivalent rate in patients with differentiated thyroid carcinoma receiving diagnostic whole-body scan after 131I therapy[J]. Int J Radiat Med Nucl Med, 2020, 44(4): 212−216. DOI: 10.3760/cma.j.cn121381-201907038-00023.[11] 陈宇导, 张峰, 吴春兴, 等. 核医学科核素治疗病房的辐射防护及管理[J]. 中华护理杂志, 2014, 49(5): 574−576. DOI: 10.3761/j.issn.0254-1769.2014.05.015.
Chen YD, Zhang F, Wu CX, et al. Radiation protection and management in the radionuclide therapy ward[J]. Chin J Nurs, 2014, 49(5): 574−576. DOI: 10.3761/j.issn.0254-1769.2014.05.015.[12] 张永学. 加强新型冠状病毒肺炎后疫情时期核医学诊疗工作的防控[J]. 国际放射医学核医学杂志, 2020, 44(10): 607−609. DOI: 10.3760/cma.j.cn121381-202009032-00086.
Zhang YX. Strengthening the prevention and control measurement during nuclear medicine diagnosis and treatment in the post-COVID-19 period[J]. Int J Radiat Med Nucl Med, 2020, 44(10): 607−609. DOI: 10.3760/cma.j.cn121381-202009032-00086.[13] 袁海娟, 林主戈, 吴春兴, 等. 131I治疗分化型甲状腺癌患者体内残留辐射剂量及病房辐射剂量的监测分析[J]. 国际放射医学核医学杂志, 2019, 43(5): 400−404. DOI: 10.3760/cma.j.issn.1673-4114.2019.05.003.
Yuan HJ, Lin ZG, Wu CX, et al. Radiation monitoring in patients with differentiated thyroid carcinoma treated with iodine-131 and their wards[J]. Int J Radiat Med Nucl Med, 2019, 43(5): 400−404. DOI: 10.3760/cma.j.issn.1673-4114.2019.05.003.[14] Remy H, Borget I, Leboulleux S, et al. 131I effective half-life and dosimetry in thyroid cancer patients[J]. J Nucl Med, 2008, 49(9): 1445−1450. DOI: 10.2967/jnumed.108.052464. [15] Halstenberg J, Kranert WT, Korkusuz H, et al. Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves' disease[J]. Nuklearmedizin, 2018, 57(2): 43−49. DOI: 10.3413/Nukmed-0941-17-11. [16] Hautzel H, Pisar E, Yazdan-Doust N, et al. Qualitative and quantitative impact of protective glucocorticoid therapy on the effective 131I half-life in radioiodine therapy for Graves disease[J]. J Nucl Med, 2010, 51(12): 1917−1922. DOI: 10.2967/jnumed.110.080473. [17] Berg GE, Michanek AM, Holmberg EC, et al. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements[J]. J Nucl Med, 1996, 37(2): 228−232. [18] Al-Jabri A, Cooke J, Cournane S, et al. Gender differences in estimating I-131 thyroid uptake from Tc-99m thyroid uptake for benign thyroid disease[J]. Br J Radiol, 2021, 94(1118): 20200700. DOI: 10.1259/bjr.20200700. [19] Jin PY, Feng HJ, Ouyang W, et al. Radiation dose rates of differentiated thyroid cancer patients after 131I therapy[J]. Radiat Environ Biophys, 2018, 57(2): 169−177. DOI: 10.1007/s00411-018-0736-7. [20] Yu F, Zhang RG, Zhang GZ, et al. Predictive value of a thyroid-absorbed dose with a shorter effective half-life on efficacy in Graves disease patients receiving iodine-131 Therapy[J]. Med Sci Monit, 2021, 27: e928796. DOI: 10.12659/MSM.928796.